A detailed history of Asset Management Corp transactions in Amgen Inc stock. As of the latest transaction made, Asset Management Corp holds 1,806 shares of AMGN stock, worth $505,806. This represents 0.3% of its overall portfolio holdings.

Number of Shares
1,806
Previous 1,790 0.89%
Holding current value
$505,806
Previous $470,000 7.23%
% of portfolio
0.3%
Previous 0.38%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

Apr 14, 2023

BUY
$225.79 - $275.2 $3,612 - $4,403
16 Added 0.89%
1,806 $436,000
Q4 2022

Jan 24, 2023

SELL
$229.03 - $291.01 $24,277 - $30,847
-106 Reduced 5.59%
1,790 $0
Q3 2022

Oct 21, 2022

BUY
$224.46 - $253.15 $13,467 - $15,189
60 Added 3.27%
1,896 $427,000
Q2 2022

Aug 01, 2022

BUY
$230.71 - $256.74 $2,076 - $2,310
9 Added 0.49%
1,836 $447,000
Q1 2022

May 03, 2022

SELL
$219.27 - $242.57 $171,030 - $189,204
-780 Reduced 29.92%
1,827 $442,000
Q4 2021

Jan 25, 2022

BUY
$198.88 - $227.6 $1,988 - $2,276
10 Added 0.39%
2,607 $587,000
Q3 2021

Oct 13, 2021

BUY
$212.27 - $248.7 $1,698 - $1,989
8 Added 0.31%
2,597 $552,000
Q2 2021

Aug 06, 2021

BUY
$233.58 - $259.14 $87,592 - $97,177
375 Added 16.94%
2,589 $631,000
Q1 2021

May 04, 2021

SELL
$221.91 - $258.6 $135,365 - $157,746
-610 Reduced 21.6%
2,214 $551,000
Q4 2020

Jan 29, 2021

BUY
$216.38 - $257.67 $357,243 - $425,413
1,651 Added 140.75%
2,824 $693,000
Q3 2020

Oct 26, 2020

SELL
$234.65 - $260.95 $35,197 - $39,142
-150 Reduced 11.34%
1,173 $298,000
Q2 2020

Jul 21, 2020

SELL
$197.81 - $242.74 $381,971 - $468,730
-1,931 Reduced 59.34%
1,323 $312,000
Q1 2020

Apr 14, 2020

BUY
$182.24 - $241.7 $101,689 - $134,868
558 Added 20.7%
3,254 $660,000
Q4 2019

Feb 04, 2020

BUY
$189.21 - $243.2 $510,110 - $655,667
2,696 New
2,696 $650,000

Others Institutions Holding AMGN

About AMGEN INC


  • Ticker AMGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 534,931,008
  • Market Cap $150B
  • Description
  • Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...
More about AMGN
Track This Portfolio

Track Asset Management Corp Portfolio

Follow Asset Management Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Asset Management Corp , based on Form 13F filings with the SEC.

News

Stay updated on Asset Management Corp with notifications on news.